newsfilter
← Latest News
GlobeNewswire·

Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022 Initiating clinical safety evaluation of hi